Phathom Pharmaceuticals, Inc. PHAT
5.49 USD -0.39 (-6.72%)
As ofNov 17, 2026, 3:18 PM EST
5.48 Day range 5.95
5.02 52-week range 18.31
- YTD
- -66.94%
- 1 year
- -61.94%
News
benzinga.com Phathom Pharmaceuticals Announces $0 Payment From Eligible Commercially Insured Patients For VOQUEZNA Tablets Through BlinkRx Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal diseases, today announced that eligible…
benzinga.com Phathom Pharmaceuticals Q3 2026 Earnings Call Transcript Phathom Pharmaceuticals (NASDAQ:PHAT) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…benzinga.com Phathom Pharmaceuticals Affirms FY2026 Sales Guidance of $310.000M-$325.000M vs $314.842M Est Phathom Pharmaceuticals (NASDAQ:PHAT) affirms FY2026 sales outlook from $310.000 million-$325.000 million to $310.000 million-$325.000 million vs $314.842 million estimate.
benzinga.com Phathom Pharmaceuticals Q3 Adj. EPS $0.04 Beats $0.02 Estimate, Sales $84.722M Miss $85.096M Estimate Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly earnings of $0.04 per share which beat the analyst consensus estimate of $0.02 by 100 percent. This is a 126.67 percent increase over losses…
